RxDoctor Payments Data

Kyu Ahn, MD

Internal Medicine · Garden Grove, CANPI 1427015593

Payments from drug & device makers

$2,112in general payments, 2019–2025

Across 91 payments — averaging $23.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amarin Pharma, Inc.$778
  • Pfizer$299
  • Nestle Healthcare Nutrition Inc.$193
  • Penumbra, Inc.$170
  • AstraZeneca$141
  • Boehringer Ingelheim$121
  • plus $410 from 9 others

What the payments were for

  • Food & beverage$2,112100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,112 in reported general payments places this provider in the 80th percentile of 13,581 internal medicine providers in California.

See all internal medicine providers in California

Medicare billing

Part B allowed, 2024
$85,714
Medicare patients
153
Services billed
991

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VascepaIcosapent Ethyl623$364,835
EliquisApixaban133$109,874
JardianceEmpagliflozin111$107,237
FarxigaDapagliflozin Propanediol42$40,190
Icosapent Ethyl176$37,436
ZenpepLipase/Protease/Amylase25$34,845
JanuviaSitagliptin Phosphate33$30,464
JanumetSitagliptin Phos/Metformin Hcl26$24,538
CreonLipase/Protease/Amylase22$22,885
OzempicSemaglutide24$21,081
LinzessLinaclotide37$18,972
EntrestoSacubitril/Valsartan21$13,635
XareltoRivaroxaban21$11,578
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog14$10,590
Atorvastatin Calcium1,065$8,993

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$299$109,874133 claims
Boehringer IngelheimJardiance$121$107,237111 claims
AbbVieCreon, Linzess$40$41,85759 claims
AstraZenecaFarxiga$141$40,19042 claims
Aimmune Therapeutics, Inc.Zenpep$48$34,84525 claims
NovartisEntresto$54$13,63521 claims
Astellas Pharma US IncMyrbetriq$20$8,74520 claims
GSKShingrix$58$2,83714 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 13,581 internal medicine providers in California.

Other internal medicine in Garden Grove

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →